January 17, 2022

SAN RAMON, CALIF., January 17, 2022—Committed to advancing new technologies that improve how eye care professionals (ECPs) deliver clinical care, CooperVision and its Specialty EyeCare unit will present a comprehensive portfolio of products, services and resources at the 2022 Global Specialty Lens Symposium (GSLS). Several professional educational sessions will champion the company’s latest contact lens innovations and evidence-based research in myopia control, myopia management, and irregular cornea. The annual event takes place in Las Vegas from January 19-22.

“CooperVision is dedicated to creating greater access to life-changing eye care technologies that address even the toughest vision challenges,” said J.C. Aragón, President, CooperVision Specialty EyeCare. “Our unmatched portfolio of innovative lens designs for myopia management, irregular cornea, and presbyopia management, empowers eye care professionals to differentiate themselves while positively impacting the lives of their patients.”

Innovations in Myopia Management and Myopia Control

With exponential growth in attention surrounding myopia progression in children, CooperVision will emphasize its extensive portfolio of leading contact lenses at GSLS. Attendees will have the opportunity to learn more about MiSight® 1 day for myopia control*, and Paragon® CRT and iSee® ortho-k lenses for myopia management.

The company will also share the recently announced seven-year results from its international MiSight® 1 day clinical study. Mean axial elongation showed no evidence of rebound, meaning that myopia control treatment gains were retained after treatment was ceased over a 12-month period.†1,2 With these results, ECPs can more confidently prescribe MiSight® 1 day contact lenses for age-appropriate* patients with myopia.

On Thursday, January 20, and Friday, January 21, CooperVision will lead multiple discussions surrounding myopia management, including:

  • Act Today, Change Tomorrow: MiSight® 1 day Certification Lunch & Learn
    Thursday, Jan. 20 | 12 – 1:30 p.m. PT
    Justin Kwan, OD, FAAO, CooperVision and Debbie Jones, BSc, FAAO, Centre for Ocular Research and Education (CORE)
  • Perspectives on Myopia Management Treatment Options | A Dialogue with your Colleagues 
    Thursday, Jan. 20 | 3:30 – 4:30 p.m. PT
    Moderator: Lyndon Jones, PhD, DSc, FCOptom, FAAO, Centre for Ocular Research and Education (CORE). Panelists: Andrew Neukirch, OD, Carillon Vision Care, and Christopher Gee, OD, Iron Horse Optometric Group.
  • Improve your Ortho-K Fitting Game | Rapid Fire Case Series with Dr. Maria Liu
    Friday, Jan. 21 | 4:15 – 5:15 p.m. PT
    Maria Liu, OD, FAAO, PhD, UC Berkeley School of Optometry, Leah Johnson, OD, FAAO, CooperVision Specialty EyeCare

Growing Momentum for New Optimized Pupil Optics (OPO)

On Friday, January 21, CooperVision Specialty EyeCare will lead a breakout session on its new Optimized Pupil Optics (OPO) for its Onefit™ Med and Onefit™ MED+ scleral contact lenses, led by Justine Siergey, OD, FSLS, Manager of Professional Affairs, CooperVision Specialty EyeCare, and M.C. Blanchard, Global Lead, Irregular Cornea. Evan Kauffman, OD of UVA Health will share his experiences with the recently-launched design, which is being rapidly adopted by scleral-fitting practices across the U.S. and worldwide.

The innovative lens design—which is supported by a user-friendly online fitting tool—enables ECPs to reposition the multifocal optics to align with the visual axis to achieve superior results and subjective vision for patients with presbyopia.

OPO lenses incorporate several markings, including a six o’clock dot indication to help patients orient the lens correctly on their eye, a circle of eight small dots at 6 mm to indicate the new center of the optics for pupil centration, plus toric hash marks notating the flat meridian as seen in other Onefit™ MED toric haptic designs.

For additional information about the company’s products, please visit CooperVision.com and CooperVisionSpecialtyEyeCare.com.

# # #

Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight 1 day.

*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

1 Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.

2 Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Maggie Munley, Counselor, McDougall Communications
maggie@mcdougallpr.com or +1-585-434-2149